Diabetes, Heart and Cardiovascular Diseases News Chronicle Diabetes, Cardiovascular and Heart Diseases. Article 61
Published on September 21, 2016 at 02:30 PM


Partnership Between Lifescan And WellDoc

Lifescan inc and WellDoc companies partnered together to provide the best type 2 diabetes (T2D) management solutions with data analysis powered by BlueStar. As per the new agreement, companies are going to integrate first FDA cleared BlueStar diabetes management platform with LifeScans blood glucose monitoring system.


       
Post a message on social media and mail to your friend and doctor to resolve your health condition. Article address TO LINK on your social media is (copy and past the code below):

Also related to this story
1. Usability Study Of WellDoc BlueStar Mobile App
2. Risks With Over Eating Of Omega-3 Fatty Acids
3. SGLT2 Inhibitor Drug Ertugliflozin
4. Chronic Kidney Disease, Heart Disease & Diabetes Prevention Drugs From Forxiga Drug Maker AstraZeneca
5. Risks To Left Ventricle And Heart Health

Lifescan Inc : Lifescan Inc is a Johnson & Johnson company having headquarters in Milpitas, California. Company manufactures and markets OneTouch Verio blood glucose monitoring system with smartphone support for homes, clinics and hospitals.

WellDoc : WellDoc, Baltimore, Maryland is a healthcare company established in 2005. Company is in software services and products business helping patients and doctors in treating chronic diseases worldwide.

 

Storing Body Fat More efficiently

Researchers from Anti-Doping Laboratory, Qatar (ADLQ) and University of Bristol, UK found that some obese people are at LOWER RISK to health complications associated with extra weight. Researchers found that stem cells of LOWER RISK people (with extra weight) are storing fat more efficiently compared with other people of the same weight. Stem cells of LOWER RISK people are not storing fat in important organs such as heart, liver and kidney. Storing fat in important organs is a high risk factor to diabetes, stroke or heart attacks. Researchers found that LOWER RISK individuals had less levels of "interleukin 6", a blood protein that controls body inflammation and infection responses. The levels of interleukin-6 are high with people having diseases associated with over weight. Now researchers are devising plans in using "interleukin-6" protein so that stem cells can store more fat in them instead of important organs during pre-diabetic stage itself and prevent type 2 diabetes (T2D). Dr Mohamed Elrayess (ADLQ) and Dr Wael Kafienah (University of Bristol) are part of the research group.


       
Post a message on social media and mail to your friend and doctor to resolve your health condition. Article address TO LINK on your social media is (copy and past the code below):

Also related to this story
1. Benefits Of Beige Fat Cells
2. Complication With Belly Fat
3. Device To Release Drugs In Eye
4. Device To Predict Diabetes
5. Role Of Pioglitazone Diabetes Drug In Preventing Breast Cancer

Stem cells : Stem cells are found in blood of an attached umbilical cord after birth. As organism ages, the stem cells takes up specialized functionality in tissues or organs such as skin, blood, bone, muscle, liver etc. For example, red cells job is oxygen delivery. But stem cells are for unspecialized purpose and can do any job or body function. Stem cells can

Important uses of stem cells are

 

Trials Of GLP-1 (exenatide extended-release) And Farxiga (dapagliflozin)
AstraZeneca had conducted phase 3 trials and announced that their drugs were successful and reached the trial end point with significant reduction in blood sugar levels in patients with type 2 diabetes (T2D). The drugs in phase 3 trials are

Phase 3 trial results were submitted at the 52nd Annual Meeting of the European Association (AMEA) in Munich, Germany . The phase 3 trial results were published in the Lancet Diabetes & Endocrinology . AstraZeneca is introducing following drugs shortly.

       
Post a message on social media and mail to your friend and doctor to resolve your health condition. Article address TO LINK on your social media is (copy and past the code below):

Also related to this story
1. Hormones GLP-1 And PYY
2. Study Of Exenatide Drug
3. Trials With Forxiga (Dapagliflozin), Victoza (Liraglutide) And Insulin Approach (Triple Therapy)
4. Device To Detect Deadly Ketones
5. About Revita DMR Device

GLP-1 : Gut endocrine cells located in epithelium of the small intestine releases incretins metabolic hormones during meals. Incretins triggers increase in production of insulin from beta cells (in pancreatic) and finally reduction in blood sugar levels after sugar absorption by body cells. There are two type of incretins hormones in humans and one of them is GLP-1 (glucagon-like peptide-1) hormone. GLP-1 receptor agonist mimic incretins hormones of GLP-1 type to increase insulin production. The drug is an injectable type of drugs to treat type ii diabetes (T2D). These drugs are capable of reducing glucagon (hormone that increase concentration of glucose in blood), reduces HbA1c levels, reduce weight. These drugs are low risk to hypoglycemia.

 

Categories

Sitemap 1   Sitemap 2   Sitemap 3   Sitemap 4

 

Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by surgeon or physician or doctor. Published article is not a medical advice by the OWNER of "Diabetes News Chronicle" website or by the AUTHOR of the article.


Published by Jammi Vasista, Chennai, India.
Email Jammi[no-space]Vasista1991[at]gmail[dot]com
Phone 91-944-578-3182.
Address Diabetes News Chronicle, No 40, Kaveri Street, Rajaji Nagar, Villivakkam, Chennai, India. Pin : 600049.